Moreover, the specificity of sLOX-1 is significantly increased when combined with CEA, indicating that serum sLOX-1 can be used as a new potential biomarker for the diagnosis of NSCLC. The gene discussed is CEACAM5; the disease is non-small cell lung carcinoma.